Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9
Nageshwar R. Budha, Maya K. Leabman, Jin Y. Jin et al. · The AAPS Journal · 2015
Cited by 17 works. doi:10.1208/s12248-015-9750-8 Open-access PDF
Authors
- Nageshwar R. Budha
- Maya K. Leabman
- Jin Y. Jin
- Daisuke Wada
- Amos Baruch
- Kun Peng
- Whittemore G. Tingley
- John D. Davis
References
- Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
- Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
- European guidelines on cardiovascular disease prevention in clinical practice: executive summary
- ESC/EAS Guidelines for the management of dyslipidaemias
- Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
- Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)